Tenaya Therapeutics, Inc. (TNYA) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $2.33 (low: $2.00, high: $3.00), representing an upside of 206.7% from the current price $0.76.
Analysts estimate Earnings Per Share (EPS) of $-1.35 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.31 vs est $-1.35 (beat +3%). 2025: actual $-0.59 vs est $-0.60 (beat +2.3%). Analyst accuracy: 97%.
TNYA Stock — 12-Month Price Forecast
$2.33
▲ +206.74% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Tenaya Therapeutics, Inc., the average price target is $2.33, with a high forecast of $3.00, and a low forecast of $2.00.
The average price target represents a +206.74% change from the last price of $0.76.
Highest Price Target
$3.00
Average Price Target
$2.33
Lowest Price Target
$2.00
TNYA Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Tenaya Therapeutics, Inc. in the past 3 months
EPS Estimates — TNYA
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.31
vs Est –$1.35
▲ 3.1% off
2025
Actual –$0.59
vs Est –$0.60
▲ 2.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TNYA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
